Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. - Wikidata - awgldk - TriplyDB

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

http://www.wikidata.org/entity/Q36229454

about

FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1 Pazopanib in the treatment of soft tissue sarcoma Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium Lymphangiogenesis is required for pancreatic islet inflammation and diabetes RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription.The herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization.Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3.Murine Notch1 is required for lymphatic vascular morphogenesis during development Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis.The lymphatic system in health and disease.Interplay between Inflammatory Responses and Lymphatic Vessels.Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation.Hypoxia influences the vascular expansion and differentiation of embryonic stem cell cultures through the temporal expression of vascular endothelial growth factor receptors in an ARNT-dependent manner.Temporal and spatial regulation of epsin abundance and VEGFR3 signaling are required for lymphatic valve formation and function Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature.Lymphatic vascular morphogenesis in development, physiology, and disease Heterogeneity of the tumor vasculature.In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis.The cutaneous vascular system in chronic skin inflammation Lymphangiogenesis and cancer Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3.Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis.Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocarcinomas.Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.Inflammation-associated lymphangiogenesis: a double-edged sword?Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis.Plasticity of airway lymphatics in development and disease.Preferential lymphatic growth in bronchus-associated lymphoid tissue in sustained lung inflammation.Lymphangiogenesis, myeloid cells and inflammation.Perspectives on lymphangiogenesis and angiogenesis in cancer.Interaction of tumor cells and lymphatic vessels in cancer progression.PlGF: a multitasking cytokine with disease-restricted activity.Type I interferon and lymphangiogenesis in the HSV-1 infected cornea - are they beneficial to the host?

P2860

Q24641842-0FACE3F4-AFC7-4174-B47F-4A4F59F4EF35 Q28269229-9B5E6C46-7DA0-493A-B09C-F2C63265DAAC Q28586394-D8F37F77-9D72-4C7E-98A7-E88A46879CD7 Q28741586-D5EDED39-C42C-41EC-885F-E302A522CA99 Q28742322-992E65E7-67BD-41E7-99A6-291BD9D57BE9 Q30560112-7E8593B3-87C1-4F5B-B798-F457530C674A Q31036498-B0E21C9C-6A88-4B64-81FA-1ABF8D4A9B02 Q33555154-526E78D7-E10E-4DC0-91D6-E4B86A5A1741 Q33616451-54FA74A0-5B7E-471E-8B19-92E0EE43B54A Q33774250-E0E66723-FA24-4399-94D8-4576AC4D2073 Q33778580-30EC44DF-55F8-4F79-AF1F-DC9BC9B77692 Q34015299-6E9C87C1-37DF-439A-8549-38226AA273E9 Q34105706-6A144A80-C87C-4A92-9378-91CE9232ED61 Q34161479-B982197A-1E7A-46DB-BAE3-BAE3F3D1687C Q34339378-E13EA9DA-9BD7-404B-83ED-102907F671A4 Q34483937-74ED1F18-14C6-4D89-9C29-8C9718AFF7EA Q34567287-3784358B-A007-4FA1-ADCD-06E97393A64F Q34984742-5E38E6C8-2451-42D5-8F2B-32E57D3ED7A6 Q35196040-42C8FC8E-E6E8-45FC-85FD-7DB0B203D46C Q35752502-F9B71585-3AFB-4225-9816-6BB038B7C7FE Q35924996-9184860D-FA76-497C-B620-6DE1E6F2BA76 Q36098582-EB87B6CF-E576-4C47-A5B8-DB5F7BD0B976 Q36137692-EFBC8F8B-B997-4012-88F0-FAEC5D1CCB94 Q36799205-BA11CAB3-33DD-4D78-9041-454106A4F695 Q36804671-7A43BA19-9A21-40A0-98A0-4A9A9571BBD6 Q37035753-5C9A2C4B-AF84-4B07-BCEE-E2EDE2FC672C Q37037233-9ADDFC44-20D7-4122-9018-9638BC7B2F54 Q37262772-791264C0-1DAA-421F-BECC-7CEC607AADBA Q37277702-B0487D95-5675-464F-A243-AAA99212CF47 Q37374986-2946A0BE-6A25-4AFD-B278-C524701E8B8C Q37551405-370FC71F-4B47-4763-B2E3-9B0E3E0D1191 Q37609665-F1CC0C27-2E0B-4473-9A4F-2763AE2F7F3B Q37610682-3C762141-B2D7-48E8-8084-DCA64158E4BF Q37639260-79EE9001-781B-49A2-B4E4-5058B9550D1F Q37734899-9AE62515-CC00-42B5-99DA-8D1EFC222866 Q37754580-30D57F20-9985-4D3D-A103-8D448D46E426 Q37863614-AD3FD2C2-C64A-4990-B06B-0C75DBFB5419 Q37969667-660AAFC1-1698-4B7E-A3A6-82E8F1BD665C Q38036234-409ABFD0-779E-492F-A034-6B33526C27BD Q38123280-90422DB6-8B85-4F06-9D90-989AEEABA130

P2860

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

http://www.wikidata.org/entity/Q36229454

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Distinct vascular endothelial ...... sel enlargement and sprouting.

@ast

Distinct vascular endothelial ...... sel enlargement and sprouting.

@en

type

label

Distinct vascular endothelial ...... sel enlargement and sprouting.

@ast

Distinct vascular endothelial ...... sel enlargement and sprouting.

@en

prefLabel

Distinct vascular endothelial ...... sel enlargement and sprouting.

@ast

Distinct vascular endothelial ...... sel enlargement and sprouting.

@en

P1433

Q36229454-A3E033B0-E784-4C72-BCB5-02D4BF21365A

P1476

Q36229454-D7C1425E-8D15-4026-BB4E-DAC70065CC29

P2093

Q36229454-19BC4CF0-3E50-4BC9-8E7B-C06DFAFE25CF

Q36229454-38E31183-CB61-42EA-A96D-12C19B3ED8CD

Q36229454-415AA5C2-3A3F-4A4E-BD6B-C47FE4E7C344

Q36229454-9FD100EF-E5C6-46B5-9E06-7579AA49983C

Q36229454-A353C52F-DD4B-4A9C-8F14-D6AFD4B33185

Q36229454-D2F2B453-6E3F-4C79-9E2C-0ED2F37D3848

Q36229454-FD47C225-3947-4AAA-B3BB-E6BF9CA0BECC

P2860

Q36229454-0176E7E7-1161-4900-83B2-2A4D5BA5012D

Q36229454-02D414FE-B56F-4BC3-AC70-E7980B320941

Q36229454-0EFD42FC-B66B-4546-B40C-17014E91CA50

Q36229454-1A1CFC47-EE98-4620-B849-DFEFE0FD57F3

Q36229454-1FAB9FDC-C608-4334-BA4C-59CD99FB7FE0

Q36229454-30262533-45DB-41FC-9CA8-F3666AEA6F42

Q36229454-32794031-A37F-4C7B-A567-27D3175A3756

Q36229454-438EDF1D-2F90-4167-9DA1-03CEDC4EE6E4

Q36229454-43956B93-FA26-46A0-BCBF-CE36BC1FC359

Q36229454-4911E9E3-D0D6-4619-B091-4A948F74EBA1

P304

Q36229454-E4055D93-07AF-4330-AC30-67C6EC9218D4

P31

Q36229454-2A805000-E651-400F-8534-0D675973221E

P356

Q36229454-8FE085F5-EAA5-4CAE-AB74-9E474AA423B6

P407

Q36229454-75EB092B-2376-412B-912F-78EE0F8DE744

P433

Q36229454-8EEB8AB3-312F-4AE5-8421-418347B88201

P478

Q36229454-D553C906-F2F3-49ED-B928-9A12329D8797

P50

Q36229454-6CAFDBC0-F03E-41CC-A26E-58F60216B547

Q36229454-876AA2F6-E2D8-4419-934A-F797534B0746

Q36229454-89ECD1D5-CC3C-4565-AC81-FC88A3A69C03

Q36229454-9AFE3047-83A7-4922-BF46-FC8B568338F8

P577

Q36229454-FA50C80D-3582-4342-9DEA-6DE11E975E48

P5875

Q36229454-2371761F-6715-46F4-9C41-D6685A7CE5A0

P698

Q36229454-FCF6525D-FEDF-467F-BE8B-7BD8364761C9

P921

Q36229454-56FDF1FF-A7AB-4B88-8C83-BBD30C332CEF

P932

Q36229454-730BE8A8-1AE5-48DF-AAC9-4B4D2B9B7B93

P356

P1433

Journal of Experimental Medicine

P1476

Distinct vascular endothelial ...... ssel enlargement and sprouting

@en

P2093

Giovanna Zambruno

http://www.w3.org/2001/XMLSchema#string

Harold F Dvorak

http://www.w3.org/2001/XMLSchema#string

Janice A Nagy

http://www.w3.org/2001/XMLSchema#string

Maria Wirzenius

http://www.w3.org/2001/XMLSchema#string

Marko Uutela

http://www.w3.org/2001/XMLSchema#string

Masabumi Shibuya

http://www.w3.org/2001/XMLSchema#string

Teresa Odorisio

http://www.w3.org/2001/XMLSchema#string

P2860

Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor

The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease

Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins

Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

Cardiovascular failure in mouse embryos deficient in VEGF receptor-3

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

Angiogenesis in life, disease and medicine

P304

1431-1440

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20062642

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

204

http://www.w3.org/2001/XMLSchema#string

P50

Seppo Ylä-Herttuala

P577

2007-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6300050

http://www.w3.org/2001/XMLSchema#string

P698

17535974

http://www.w3.org/2001/XMLSchema#string

P921

P932

2118625

http://www.w3.org/2001/XMLSchema#string